A Pilot Phase I Randomized Study to evaluate | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 1

12 participants needed

1 Location

Brief description of study

Our pilot study will evaluate whether the activation of antiviral innate mechanisms by administration of Pegylated Interferon alpha 2b (peg-IFN-2b) when combined with two broadly neutralizing antibodies (3BNC117 and 10-1074) in HIV positive participants with well controlled viral replication can result in viral control in the absence of ART or immune based therapy during a monitored analytical treatment interruption.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 12 Dec 2019. Study ID: 833816

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).